Phaseline

Companies › Hangzhou Sumgen Biotech

Hangzhou Sumgen Biotech: clinical trials, targets and expected readouts

3 active drug programs in 6 registered trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Oncology, Hematology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SG301 SC–Phase 3Relapsed/Refractory Multiple Myeloma; Primary Immune Thrombocytopenia; Systemic Lupus Erythematosus (SLE); Relapsed or Refractory Multiple MyelomaDec 2026
SG1906
anti-CLDN18.2 antibody or antibody-drug conjugate
CLDN18Phase 1Locally Advanced Unresectable or Metastatic Solid TumorsFeb 2027
SG2918–Phase 1Relapsed/Refractory Multiple MyelomaSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04684108SG301 SCPhase 1Relapsed or Refractory Multiple MyelomaOncologyDec 2026
NCT05857332SG1906Phase 1Locally Advanced Unresectable or Metastatic Solid TumorsOncologyFeb 2027
NCT06508983SG301 SCPhase 3Relapsed/Refractory Multiple MyelomaOncologyMar 2027
NCT07710248SG301 SCPhase 2Primary Immune ThrombocytopeniaHematologyMay 2027
NCT07454187SG2918Phase 1Relapsed/Refractory Multiple MyelomaOncologySep 2027
NCT07447986SG301 SCPhase 2Systemic Lupus Erythematosus (SLE)ImmunologySep 2027

Targets

CLDN18 (1)

Companies with the same targets

Astellas AstraZeneca RemeGen Shanghai Institute Of Biological Products Beijing Biotech Sichuan Kelun-Biotech Biopharmaceutical Biokin (Shanghai) Biopharmaceutical Transcenta Therapeutics (Hangzhou) Shanghai Hengrui Pharmaceutical Innovent Biologics (Suzhou)

Companies built like this

Biokin (Shanghai) Biopharmaceutical LaNova Medicines Zhejiang Alentis Therapeutics Antengene Biologics Dong-A ST

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.